Abstract
Several new N-substituted 1,2-benzisothiazol-3(2H)-ones (BITs) were synthesised through a facile synthetic route for testing their anti-dengue protease inhibition. Contrary to the conventional multistep synthesis, we achieved structurally diverse BITs with excellent yields using a two-step, one-pot reaction strategy. All the synthesised compounds were prescreened for drug-like properties using the online Swiss Absorption, Distribution, Metabolism and Elimination (SwissADME) model, indicating their favourable pharmaceutical properties. Thus, the synthesised BITs were tested for inhibitory activity against the recombinant dengue virus serotype-2 (DENV-2) NS2BNS3 protease. Dose–response experiments and computational docking analyses revealed that several BITs bind to the protease in the vicinity of the catalytic triad with IC50 values in the micromolar range. The DENV2 infection assay showed that two BITs, 2-(2-chlorophenyl)benzo[d]isothiazol-3(2H)-one and 2-(2,6-dichlorophenyl)benzo[d]isothiazol-3(2H)-one, could suppress DENV replication and virus infectivity. These results indicate the potential of BITs for developing new anti-dengue therapeutics.
Highlights
IntroductionMosquito-borne disease prevalence is on the rise in Asia, South America, Africa and along the Atlantic Gulf coasts of the United States
The epidemics of flaviviral diseases have been recognised for more than 200 years
These results indicate the potential of BITs for developing new anti-dengue therapeutics
Summary
Mosquito-borne disease prevalence is on the rise in Asia, South America, Africa and along the Atlantic Gulf coasts of the United States. Dengue virus (DENV) is transmitted in humans via the bite of the female Aedes aegypti mosquito. It has become one of the most emerging and prevalent pathogens [1] in tropical and subtropical regions. The clinical manifestation of DENV infection is dengue fever (DF), which in most cases is characterised by milder and self-limiting symptoms, such as febrile illness, headache, muscular pain and skin rashes [2]. A significant number of DENV infected patients are prone to more advanced and fatal diseases, such as dengue shock syndrome (DSS) and dengue haemorrhagic fever (DHF) [3]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have